drugset / Trial / NCT00581555

Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy

NCT00581555

Phase 4 Completed 120 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the use of etanercept as a replacement therapy for ciclosporin in patients with plaque psoriasis.

Timeline

Start
2007-10
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications